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An absolute prerequisite for a therapeutic vaccine 
against hepatitis C virus (HCV) infection is the potency 
to induce HCV-specific vigorous and broad-spectrum 
T-cell responses. Here, we generated three HCV vaccines 
based on a recombinant Semliki Forest virus (rSFV) vector 
expressing all- or a part of the conserved nonstructural 
proteins (nsPs) of HCV. We demonstrated that an rSFV 
vector was able to encode a transgene as large as 6.1 kb 
without affecting its vaccine immunogenicity. Prime-
boost immunizations of mice with rSFV expressing all 
nsPs induced strong and long-lasting NS3-specific CD8+ 
T-cell responses. The strength and functional heteroge-
neity of the T-cell response was similar to that induced 
with rSFV expressing only NS3/4A. Furthermore this 
leads to a significant growth delay and negative selec-
tion of HCV-expressing EL4 tumors in an in vivo mouse 
model. In general, as broad-spectrum T-cell responses 
are only seen in patients with resolved HCV infection, 
this rSFV-based vector, which expresses all nsPs, induc-
ing robust T-cell activity has a potential for the treatment 
of HCV infections.
Received 16 October 2013; accepted 17 December 2013; advance online 
publication 28 January 2014. doi:10.1038/mt.2013.287
INTRODUCTION
Hepatitis C virus (HCV) infection is a major cause of liver dis-
ease and the primary cause for liver transplantation in the western 
world. The World Health Organization estimated that ~150 mil-
lion people worldwide, i.e., around 2.5% of the world population, 
are chronically infected with HCV. Sixty to 70% of these patients 
develop chronic liver disease such as liver fibrosis and cirrhosis 
and 1–5% of these patients develop liver cancer within 10–40 
years after infection.1 The former standard of care treatment, a 
combination of antiviral agents, pegylated interferon-α and riba-
virin, achieved sustained viral response in less than 50% of the 
patients with chronic HCV (CHC) infected with HCV genotype 
1.2 Currently, in some countries, this standard of care treatment is 
being combined with the novel HCV protease inhibitors bocepre-
vir and telaprevir, resulting in a sustained viral response of ~70% 
in patients infected with HCV genotype 1.3,4 Yet these drugs are 
not widely available, the drugs are not always tolerated and not all 
genotypes respond equally to interferon and the antiviral drugs. 
In contrast to vaccines against hepatitis A and B virus, there is 
no prophylactic HCV vaccine available, amongst other reasons 
due to the high variability of the structural proteins of the virus. 
Therapeutic vaccines, aimed at inducing T-cell responses against 
the more conserved proteins of the virus are therefore urgently 
needed. These vaccines can possibly be used as single treatment 
modalities or can be combined with standard antiviral treatments.
HCV-specific adaptive cellular immunity plays an essential 
role to control HCV infection, particularly in the induction of 
functional HCV-specific T cells5 as also exemplified by the follow-
ing observations. The presence of NS3/4A-specific CD8+ T cells 
is positively correlated with a sustained viral response.6–8 Patients 
who develop CHC have a narrow-spectrum and low number of 
HCV-specific T cells in both circulating blood and liver.5 A low 
ratio of the HCV-specific CD8+ T cells to the nonspecific CD8+ 
T cells in infected liver leads to an ineffective clearance of virus 
and a nonspecific inflammation.9 Next, dysfunctional HCV-
specific T cells with reduced IL-2 secretion and cytotoxic activities 
are being observed in patients with CHC,10,11 and surprisingly, also 
in patients who recovered from chronic HCV infection by IFN/
ribavirin treatment.12 Moreover, the longer the duration of the 
exposure of HCV antigen, the deeper the level of T-cell exhaus-
tion.12 Thus, immunotherapeutic approaches against HCV, should 
not only induce de novo HCV-specific T-cells production but also 
restore T-cell function.
Several immunotherapeutic approaches are being devel-
oped to induce HCV-specific immune responses.13 Among 
those approaches, viral vectors induce the most robust immune 
response in both preclinical and clinical settings. In this study, 
recombinant Semliki Forest virus (rSFV) vector, which induces 
strong and long-lasting antigen-specific response,14 was used to 
develop a therapeutic vaccine against HCV. The nonstructural 
proteins (nsPs) of HCV have been identified as promising vaccine 
targets due to the fact that they are genetically conserved, essential 
for viral replication and most importantly, immunogenic. In an 
effort to improve immune responses against the nsPs of HCV, we 
generated three rSFV constructs encoding either the entire nsPs of 
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HCV (1. NS2′-5B′) or parts of these proteins of HCV (2. NS3/4A 
and 3. NS5A/B′). The in vivo efficacy of these rSFV-based vaccines 
was determined in naïve and tumor-bearing mice.
RESULTS
Characterization of rSFV encoding the entire or the 
part of HCV nsPs
Aiming to induce immune responses against the entire or part of 
the HCV nsPs, three rSFV expressing (i) NS2′-5B′, (ii) NS3/4A, 
and (iii) NS5A/B′ proteins of HCV, were designed and produced 
(Figure 1a). Production and stability of the HCV nsPs synthesized 
by rSFV infected BHK-21 cells were determined by 35S-methionine 
pulse labeling (Figure 1b). Incubation with rSFVeNS3/4A induced 
production of the NS3/4A fusion protein (75.9 kDa) and the NS3 
protein (70 kDa) by BHK-21 cells. On the other hand, cells incu-
bated with rSFVeNS2′-5B′ synthetized five distinct proteins, cor-
responding to the NS2/3/4A fusion protein (86.9 kDa), the NS2/3 
fusion protein (81 kDa), the NS5B protein (60.8 kDa), the NS5A 
protein (49 kDa), and the NS4B protein  (28.7 kDa). Cells incu-
bated with rSFVeNS5A/B′ produced one NS5A/B fusion protein 
(109.8 kDa). Cells incubated with control rSFVe or buffer were 
negative controls. Proteins expression was also determined by 
western blotting stained with anti-NS3 and anti-NS5A antibodies 
(data not shown). The newly constructed rSFVs induced abun-
dant expression of HCV nsPs which were stably expressed till 22 
hours after incubation with rSFVs.
Frequencies and phenotypes of NS3-specific T cells 
induced by rSFV immunizations
Next, to verify the immunogenicity of these newly constructed 
rSFV vaccines in vivo, mice were intramuscularly primed and 
boosted with 5 × 106 purified rSFV or buffer (phosphate-buffered 
saline (PBS)) with a 2-week interval and the in vivo induction of 
NS3-specific T-cells response was evaluated. Ten days after the 
last immunizations, NS3-specific CD8+ cells were identified by 
GAVQNEVTL-dextramer and the phenotype of these cells was 
studied. The peptide GAVQNEVTL is derived from HCV NS3 
and has been identified as a potent cytotoxic T  lymphocytes 
(CTL) epitope presented by the major histocompatibility com-
plex (MHC) class I molecule H-2Db of C57BL/6 mice.15 Both 
rSFVeNS2′-5B′ and rSFVeNS3/4A immunizations induced 
potent NS3-specific CD8+ T-cell responses, yet mice immu-
nized with rSFV encoding only NS3/4A had higher frequen-
cies than mice immunized with rSFV encoding the entire HCV 
nsPs (rSFVeNS2′-5B′: 2.2% ± 0.4% versus rSFVeNS3/4A: 5.5% ± 
0.4%, P < 0.05) (Figure 2a). The NS3-specific CD8+ T cells were 
classified into three subsets, corresponding (i) central memory 
T  cells (TCM, CD44+CD62L+CD127+), (ii) effector memory 
T  cells (TEM, CD44+CD62L−CD127+), and (iii) effector T cells 
(Teff, CD44+CD62L−CD127−). The total number of each T-cell 
subset in the spleen is shown (Figure 2b). The increased number 
of the total NS3-specific CD8+ T cells in mice immunized with 
rSFVeNS3/4A (Figure 2a) was mainly due to the increase in the 
number of TEM cells and Teff cells (P < 0.05). Immunization with 
rSFV encoding either the entire or the part of HCV nsPs induced 
NS3-specific responses with similar frequencies of TCM cells.
Effector function of HCV-specific CD8+ cells
In order to investigate the spectrum of the HCV-specific 
response, spleen cells from rSFV-immunized mice were stimu-
lated with stimulants containing the entire or part of the HCV 
nsPs and the effector functions of HCV-specific CD8+ T cells 
were determined. The stimulants were Hepa1-6V cells, Hepa1-6V-
NS2′-5B′ cells, or the HCV synthetic peptides, GAVQNEVTL or 
ILDSFDPL. Hepa1-6V-NS2′-5B′ cells are murine hepatoma cells 
expressing HCV NS2′-5B′ protein as well as a yellow fluores-
cence reporter protein, VENUS (abbreviated to V) and Hepa1-
6V cells are mock transduced cells expressing VENUS protein 
only (Supplementary Figure S1). The peptide ILDSFDPL has 
been recently identified as a HCV NS5A CTL epitope pre-
sented by the MHC class I molecule, H-2Kb of C57BL/6 mice.16 
Figure 1 Stable expression of hepatitis C virus (HCV) nsPs in vitro. 
(a) Size of plasmid Semliki Forest virus (SFV), number is the nucleotide 
position in the plasmid DNA containing full genome of HCV 1a (H/FL). 
(b) BHK-21 cells were incubated with rSFVeNS2′-5B′, rSFVeNS3/4A, 
rSFVeNS5A/B′, or rSFVe. “No rSFV” was negative control cultured in 
medium only. Cells were pulsed with 35S-methionine for 1 hour at 6 
hours after addition of rSFV and were further cultured for 1, 6, or 18 
hours. Radioactively labeled proteins were revealed by autoradiography 
after 12% SDS-PAGE. The molecular weight of each nonstructural pro-
tein is as following: NS2′: 11 kDa, NS3: 70 kDa, NS4A: 5.9 kDa, NS4B: 
28.7 kDa, NS5A: 49 kDa, NS5B′: 60.8 kDa. Vertical lines on the upper 
image show where separate lanes from the same gel were juxtaposed 
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Figure 2 Induction of polyfunctional hepatitis C virus (HCV)-specific CD8+ cells by recombinant Semliki Forest virus (rSFV) immunizations. 
Mice were primed and boosted intramuscularly with 5 × 106 rSFV or phosphate-buffered saline (PBS) with a 2-week interval. Ten days after the last 
immunization, mice were sacrificed and splenocytes were isolated for phenotypic analysis using flow cytometry. (a) NS3-specific CD8+ cells are 
shown as a percentage of total CD8+ cell population. Data represent two independent experiments showing similar result (n = 2–4). (b) Absolute 
numbers of TCM (CD44
+CD62L+CD127+), TEM (CD44
+CD62L−CD127+), and Teff (CD44
+CD62L−CD127−) cells of the total NS3+CD8+CD44+ cell 
population in the spleen. (c) Splenocytes were stimulated with Hepa1-6V-NS2′-5B′ cells, GAVQNEVTL or ILDSFDPL peptides for 4 hours and subjected 
to surface and intracellular cytokines staining. The frequencies of each T-cell subset in the CD8+ cell population are shown. Background (PBS immu-
nized) subtraction was applied. (d) Pie charts present the mean frequencies of T-cell subsets. (c,d) 1, single producers; 2, double producers; 3, triple 
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The binding affinities of both synthetic peptides were confirmed 
on RMA-S cells. The GAVQNEVTL peptide bound to H-2Db 
at as low as 0.3 μmol/l, while the ILDSFDPL peptide bound to 
H-2Kb at higher concentration (>30 μmol/l) (Supplementary 
Figure S2). In vitro stimulation with the Hepa1-6V-NS2′-5B′ 
cells or GAVQNEVTL peptide induced degranulation 
(CD107a/b+) and secretion of multiple cytokines by CD8+ cells 
from mice immunized with rSFVeNS2′-5B′ and rSFVeNS3/4A 
(Figure 2c,d). However, very weak response was detected in 
mice immunized with rSFVeNS5A/B′. Stimulation with nei-
ther Hepa1-6V cells (Supplementary Figure S3) nor ILDSFDPL 
induced multifunctional CD8+ T cells (Figure 2c,d). Of note, 
immunization with rSFVeNS2′-5B′ and rSFVeNS3/4A increased 
the frequencies of polyfunctional CD8+ T cell subsets that pro-
duced more than 1 cytokine (e.g., CD107a/b+IFN-γ+TNF-α+ 
and CD107a/b+IFN-γ+TNF-α+IL-2+ populations) to similar 
level upon specific stimulations (Figure 2d). Lower numbers of 
NS3-specific CD8+ cells were detected in mice immunized with 
rSFV encoding the entire HCV nsPs, the effector functions of 
these HCV-specific CD8+ cells were similar to mice immunized 
with rSFV expressing NS3/4A only.
Induction of HCV-specific CTL with rSFV 
immunizations
The most important criterion for functional effector T cells is 
the ability to lyze their target cells, which, in this study, are the 
HCV-infected cells. Therefore, the cytolytic activity of HCV-
specific CTLs was investigated in vitro (Figure 3b–d) and 
in vivo (Figure 3e). CTL activity was determined 10 days after 
the last immunization. To detect cytotoxicity in vitro, spleen 
cells isolated from immunized mice were restimulated with 
the Hepa1-6V-NS2′-5B′ cells for 7 days. The number of NS3-
specific CD8+ T cells induced after 7-day restimulation was 
higher in mice immunized with rSFVeNS3/4A (58.2% ± 15.8%) 
than in mice immunized with rSFVeNS2′-5B′ (27.6% ± 7.0%) 
(P < 0.05) (Figure 3a). This correlated with the higher num-
ber of precursor cells in mice immunized with rSFVeNS3/4A 
(Figure 2a). Restimulated CTLs from mice immunized with 
rSFVeNS2′-5B′ or rSFVeNS3/4A lysed Hepa1-6V-NS2′-5B′ cells 
(Figure 3b) and GAVQNEVTL-pulsed EL4 cells (Figure 3c) to 
a similar extent. In general, there was a higher cytotoxic activity 
against the GAVQNEVTL-pulsed EL4 cells than the Hepa1-6V-
NS2′-5B′ cells. The ILDSFDPL-pulsed EL4 cells were not lysed 
in all groups of mice (Figure 3d). Since the cytotoxic effect on 
Hepa1-6V-NS2′-5B′ cells revealed activity against unidentified 
HCV nsPs epitopes, this may mimic the real situation during 
HCV infection when infected liver cells present multi-epitopes. 
To determine CTL activities in vivo, rSFV prime-boost immu-
nized mice were adoptive-transferred with autologous sple-
nocytes pulsed with HCV peptides and irrelevant peptides 10 
days after the boost immunizations. The GAVQNEVTL-pulsed 
autologous splenocytes were lysed in mice immunized with 
either rSFVeNS2′-5B′ (90.5% ± 6.7%) or rSFVeNS3/4 (97.9% 
± 2.2%) (Figure 3e). No cytotoxic effect on the ILDSFDPL-
pulsed autologous splenocytes was detected in all groups of 
mice. Of note, cytotoxic activity was more potent in vivo though 
no extra restimulation of HCV-specific cells was performed. 
The cytotoxic effector on peptide-pulsed EL4 cells or spleno-
cytes and Hepa1-6 cells expressing all HCV nsPs indicated the 
potency of these rSFV vaccines inducing functional HCV nsPs–
specific CTL in vivo.
Therapeutic effect of the rSFV immunizations against 
EL4 tumor cells
Next, we tested the potencies of these rSFV vaccines to eradicate 
established HCV nsPs–expressing tumor. Mice subcutaneously 
inoculated with EL4V-NS3/4A cells, expressing only HCV NS3 
and NS4A, were immunized three times with rSFVeNS2′-5B′, 
rSFVeNS3/4A or PBS on days 2, 9, and 16 after tumor inocula-
tion. Mice inoculated with EL4V-NS5A/B′ cells, expressing only 
HCV NS5A and NS5B, were treated with either rSFVeNS2′-5B′, 
rSFVeNS5A/B′ or PBS with the same immunization schedule. 
These EL4 tumor cells express diverse levels of HCV nsPs and 
VENUS protein mimicking the expression of nsPs by naturally 
HCV-infected hepatocytes (Supplementary Figure S4). With 
this immunization schedule, the expansion phase of effector 
T  cells after the third immunizations will take place during 
the exponential growth of tumor cells (days 15–20 after tumor 
inoculation) as observed in PBS-treated mice. Immunizations 
with both rSFVeNS2′-5B′ and rSFVeNS3/4A induced delay 
in growth of EL4V-NS3/4A cells (P < 0.001) (Figure 4a). Of 
note, immunizations with rSFVeNS3/4A synchronized the rate 
of tumor growth that was not observed in PBS-treated mice 
(Supplementary Figure S5a). An immunization effect on EL4V-
NS5A/B′ cells was undetectable (Figure 4a and Supplementary 
Figure S5b).
The effect of immunizations on EL4 tumor cells was further 
analyzed by analyzing the expression of VENUS protein, being 
coexpressed with the HCV nsPs. EL4 tumor cells were isolated 
at different time points when the tumor volume reached ~1 cm3. 
VENUS+ cells frequencies were reduced in EL4V-NS3/4A tumor 
cells in rSFV-immunized mice but not in PBS control (P < 0.01) 
(Figure 4b). VENUS expression levels within the VENUS+ cell 
population (Supplementary Figure S5c) and total EL4V-NS3/4A 
cell population (Supplementary Figure S5d) was also reduced. 
This effect was not time-dependent as expression differences 
between groups of mice were detected in mice that were sacri-
ficed on the same day. There was no reduction of the number of 
VENUS+ cells (Figure 4b) and the expression level of VENUS 
in VENUS+ cells (Supplementary Figure S5c) and total EL4V-
NS5A/B′ tumor cells (Supplementary Figure S5d) remained the 
same in all groups of mice. Immunizations with rSFVeNS2′-5B′ 
or rSFVeNS3/4A delayed tumor growth by reducing the HCV 
NS3/4A expression and the number of VENUS+ cells in the 
tumor mass.
To investigate the effect of T cells during the early formation 
of tumor, the first rSFV immunization was performed before 
tumor inoculation. Mice were immunized with 5 × 106 rSFV 
particles on day −5, followed with EL4V-NS3/4A cells inocula-
tion on day 0. Mice were then boosted with rSFV particles twice 
on day 2 and day 9 after tumor inoculation. The effect on the 
growth of tumor was mild (Figure 5a). Nevertheless, immuniza-
tions with rSFVeNS2′-5B′ and rSFVeNS3/4A induced reduction 
on the number of VENUS+ cells (Figure 5b) and expression 
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of VENUS in the VENUS+ cell (Supplementary Figure S6b) 
and total EL4V-NS3/4A cell (Supplementary Figure S6c). The 
immunization effect on EL4V-NS5A/B′ was not determined. In 
both late and early immunization setups, both rSFVeNS2′-5B′ 
and rSFVeNS3/4A particles reduced the expression of VENUS 
and the frequencies of VENUS+ EL4 cells demonstrating the 
activity of HCV-specific CD8+ cells in vivo.
DISCUSSION
Therapeutic vaccination against HCV infection aims to induce 
robust cellular immunity against conserved HCV proteins 
leading to eradication of HCV-infected liver cells. Here, we 
demonstrated that an rSFV-based viral vector vaccine encod-
ing HCV NS3/4A as well as an rSFV vaccine encoding all 
HCV nsPs induced strong T-cell response against an epitope 
Figure 3 Induction of hepatitis C virus (HCV)-specific cytotoxic T lymphocytes (CTL) with recombinant Semliki Forest virus (rSFV) immu-
nizations. Mice were primed and boosted intramuscularly with 5 × 106 rSFV or phosphate-buffered saline (PBS) with a 2-week interval. Ten 
days after the last immunization, mice were sacrificed and splenocytes were isolated for in vitro bulk CTL assay. Splenocytes were cultured with 
irradiated Hepa1-6V-NS2′-5B′ cells at a ratio of 25:1. After a 7-day culture, splenocytes were subjected to (a) NS3-dextramer staining and (b–d) 
bulk CTL assay. Bulk CTL assay was performed by coculturing effector cells, splenocytes, with 51Chromium pulsed target cells at the indicated 
E:T ratios for 4 hours. Various target cells, (b) Hepa1-6V-NS2′-5B′ cells, EL4 cells pulsed with either (c) GAVQNEVTL or (d) ILDSFDPL peptides, 
were cocultured with restimulated splenocytes. (e) For in vivo CTL assay, mice were immunized with the same protocol and were intravenously 
transferred with peptides-pulsed fluorochromes-labeled autologous splenocytes on day 10 after the last immunization. Each mouse received a 
mixture of autologous splenocytes containing SIINFEKL-pulsed CFSElo-labeled, GAVQNEVTL-pulsed CFSEhi-labeled and ILDSFDPL-pulsed TRITIC-
labeled splenocytes at a 1:1:1 ratio. Mice were sacrificed at 14 hours after adaptive transferred. Splenocytes were isolated and the presences of 
transferred splenocytes were analyzed using flow cytometry. Data represent (a) mean and (b–e) mean ± SD of two to three independent experi-
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within the HCV NS3 protein. This NS3-specific T-cell popula-
tion consisted of both effector and memory cells. Furthermore, 
these induced NS3-specific T cells were polyfunctional, secret-
ing multiple proinflammatory Th1 cytokines and possessed 
cytolytic activity against HCV nsPs–expressing cells in vitro 
and in vivo. Immunizations partially protected mice from 
HCV NS3/4A-expressing tumor formation. Vaccine-induced 
immune  pressure on the tumors lead to selection of tumor cells, 
resulting in decreased frequencies of HCV NS3/4-expressing 
EL4 cells and reduced expression levels of the transgene 
(NS3/4A-VENUS).
To our knowledge, this is the first time showing that an rSFV 
vector retains its immunogenicity when expressing a foreign 
transgene as large as 6.1 kb. Previously, it has been shown that 
rSFV expressing a smaller transgene, HCV NS3/4A, induced 
NS3-specific CTLs.17 Due to the limitation of the cellular pro-
tein synthesis machinery, increasing the size of the transgene will 
lower the expression of each protein. As a result, vaccine immu-
nogenicity may be reduced or even lost. We demonstrated that 
an rSFV vector could be packed with all HCV nsPs, expressing 
all intact HCV nsPs, and induced a HCV NS3–specific response, 
although this response was lower than the response induced by 
rSFV expressing HCV NS3/4A only. Thus, the immunogenicity of 
rSFV vector is maintained even when a large transgene is inserted. 
Increasing the size of foreign transgenes allows broadening of the 
spectrum of T-cell responses which is considered essential for the 
induction of protective HCV immunity.18–20
T-cell responses against HCV2252–2259 ILDSFDPL, an epit-
ope recently identified by Holmstrom, F and colleagues,16 was 
not detectable this study. It should however be noted that the 
ILDSFDPL-specific T-cell responses were identified in mice 
immunized with DNA plasmid expressing NS5A only. Expressing 
more than one protein may lead to increase competition between 
epitopes resulting in reduced responses against subdominant 
epitopes.21 Yet to allow a non-HLA restricted application of 
HCV vaccines expression of as many relevant proteins as pos-
sible is desirable. Other T-cell epitopes in HCV nsPs were pre-
dicted with mathematic algorithms including SYFPEITHI,22 
NetMHCpan 2,823 and Immune Epitope Database and Analysis 
Resource (IEDB).24 The MHC affinity of the identified peptides 
was determined and the peptides were used to restimulate spleno-
cytes from rSFVeNS2′-5B′ and rSFVeNS5A/B′ immunized mice. 
Minor T-cell responses against NS2139–147, NS5B2–10 and NS5B157–165 
were observed in both groups of mice (manuscript in prepara-
tion). Nevertheless, rSFV-based vaccines encoding all possible 
T-cell epitopes allow induction of a unique spectrum of immune 
response depending on the patient’s HLA alleles.
The magnitude of a T-cell response is positively cor-
related with the dominance of its cognate epitope.25 
Activation of T cells against a protective but not pathogenic 
Figure 4 Therapeutic effects of recombinant Semliki Forest virus (rSFV) immunizations against EL4 tumor cells. Naïve mice were subcutane-
ously inoculated with 5 × 105 of EL4V-NS3/4A or EL4V-NS5A/B′ cells. Mice were then immunized intramuscularly with 5 × 106 rSFV on days 2, 9, and 
16 after tumor inoculation. (a) Survival curve is determined when tumor volume equals to 1 cm3. (b) Mice were sacrificed when the volume of tumor 
exceeded 1 cm3. Tumor cells were isolated to analyze the frequency of VENUS+ cells in the EL4V-NS3/4A and EL4V-NS5A/B′ cell population using flow 
cytometry. Cumulative results of two independent experiments with n = 5–7 are presented. ***P < 0.001, **P < 0.01.
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immunodominant epitope results in control of virus-induced 
diseases.26 We observed induction of CD8+ T-cell responses 
against an immunodominant epitope located in the HCV NS3 
protein in mice immunized with rSFV expressing either NS3/4A 
or all HCV nsPs. In the latter group however, lower frequencies 
were observed. Since the anti-tumor effect of both rSFV vec-
tors was similar, this suggests that T-cell responses against this 
immunodominant T-cell epitope are protective when a thresh-
old frequency is reached.27
On the other hand, activation of T cells against one immuno-
dominant epitope facilitates selection of viral escape mutants.28,29 
Furthermore, enhanced responses against immunodominant 
epitopes will reduce or even abrogate response against subdomi-
nant T-cell epitopes narrowing the T-cell repertoire.26,30 Therefore, 
T-cell responses against subdominant epitopes are desirable.31,32 
Interestingly, we observed a decreased response against the 
immunodominant epitope (HCV1629–1637 GAVQNEVTL) in mice 
immunized with rSFV expressing all HCV nsPs as lower frequen-
cies of GAVQNEVTL-specific T cells were detected which may 
indeed allow enhanced responses against other subdominant 
epitopes.33
The functionality of de novo induced antigen-specific CD8+ 
cells is also a reliable indicator for effective immunizations.34 A hall-
mark of an effective antiviral T cell is the secretion of multiple Th1 
cytokines including IFN-γ, TNF-α, and IL-2.34 IFN-γ and TNF-α 
mediate control of intracellular infections synergistically35 while 
IL-2 strongly enhances the expansion of both CD4+ and CD8+ 
T cells and the development of memory cells.36 Furthermore, it 
has been shown that IFN-γ reduces the expressing of HCV nsPs 
in vitro.37 In a recent study, heterologous prime-boost immuniza-
tions with a DNA and a MVA vaccine successfully enhanced the 
number of multifunctional T cells.38 In our study, with homolo-
gous prime-boost rSFV immunizations, function-active HCV-
specific T cells secreting IL-2, IFN-γ, and TNF-α were induced. In 
addition, we showed that the HCV-specific T-cell population con-
tained not only effector T cells, but also high numbers of cells with 
a memory phenotype (both TCM and TEM cells). Central memory 
T cells have a high proliferation rate and are high producers of 
IL-2, whereas effector memory cells are potent producers of IFN-
γ and cytotoxic granules.39 Phenotype and cytokine secretion of 
HCV-specific T cells reflect the potency of rSFV-based vaccines. It 
would be highly interesting to study the immunogenicity of rSFV 
vectors in mice or other animal models with exhausted T cells as 
patients with CHC have dysfunctional T cells.10,11
Small animal models susceptible for HCV infection are not 
available yet, and still under development.40 To investigate the 
immunogenicity of our rSFV-based HCV vaccines, we therefore 
produced a polyclonal EL4 tumor cells line by transducing EL4 
with HCV nsPs–expressing lentivirus. These tumor cells are het-
erogeneous, expressing variable levels of HCV nsPs as indicated 
by the expression level of the cotransduced reporter gene VENUS. 
Also, in natural HCV infections, this heterogeneity in expres-
sion level occurs because of the HCV genetic diversity within a 
host.41–43 Eradication of these heterogenic tumors involved nega-
tive selection and lysis of the VENUShi tumor cells by tumor-
specific CD8+ T cells. Furthermore, the kinetics of effector CD8+ 
T-cell responses plays a crucial role on the developing tumor. In 
this EL4 model, tumor developed exponentially from days 15 to 
25 after tumor inoculation. To investigate the therapeutic efficacy 
of the rSFV-based HCV vaccines, immunizations were scheduled 
such that the peak of CD8+ T-cell responses overlapped with 
the exponential growth of the EL4 tumor. Since immunizations 
were given after tumor inoculation, time for negative selection of 
VENUShi EL4 cells was short (approximately from day 6 to day 
15). As a result, eradication of tumor cells occurred during the 
expansion and plateau phases of T-cell response but the reduc-
tion of VENUS expression was moderate. In other immunization 
setups when immunization was given before tumor inoculation, 
tumor cells were exposed to activated T cells for longer time (from 
day 0 to day 15) allowing more selection pressure on VENUShi 
cells resulting in a significant reduction of the expression of 
VENUS. However, selection alone was not enough for eradica-
tion of this fast-growing tumor as the VENUSlo cells escaped from 
the immune responses and started to grow exponentially dur-
ing the contraction phase of T-cell responses. Therefore, rSFV-
based HCV immunizations induced immune pressure on HCV 
nsPs–expressing cells resulting in lower expression of HCV nsPs. 
Furthermore, the development of the nsPs-expressing EL4 tumor 
Figure 5 Effect of early immunizations with rSFVeNS2′-5B′ and 
rSFVeNS3/4A against EL4V-NS3/4A tumor cells. Mice were intramus-
cularly immunized thrice with 5 × 106 recombinant Semliki Forest virus 
(rSFV) on days −5, 2, and 9. On day 0, immunized mice were subcutane-
ously inoculated with 5 × 105 of EL4V-NS3/4A cells. (a) Survival curve is 
determined when tumor volume equals 1 cm3. (b) Mice were sacrificed 
when the volume of tumor exceeded 1 cm3. Tumor cells were isolated 
and the frequencies of VENUS+ cells in the EL4V-NS3/4A cell population 
were analyzed using flow cytometry. Data represent results from one 
independent experiments with n = 7.
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was delayed by the presence of the robust HCV-specific T-cell 
responses.
To conclude, rSFV encoding the entire HCV nsPs is a potent 
vaccine inducing robust and effective HCV-specific immunity. 
Immune pressure was exerted on HCV nsPs–expressing tumor 
cells reducing the expression and frequencies of HCV nsPs–
expressing tumor cells. The next step will be to study combina-
tions of therapeutic vaccines with other immune interventions 
and/or direct acting antiviral drugs. For example, PD1/CTLA-4 
blockage44,45 and anti-TIM3 treatment46 have been shown to 
restore HCV-specific dysfunctional T cells in vitro, while direct 
acting antiviral drugs aimed to reduce viral load result in reduced 
production of viral mutants as well as a decreased T-cell exhaus-
tion.47 Combined treatment of a potent HCV-specific vaccine with 
immune interventions and/or direct acting antiviral drugs will 
hopefully result in de novo HCV-specific T cells and restoration 
of existing dysfunctional T cells resulting in a better prognosis in 
patients at various stages of HCV infection.
MATERIALS AND METHODS
Cell culture. Baby hamster kidney cells (BHK-21, ATCC #CCL-10) were 
obtained from the American Type Culture Collection and were main-
tained in RPMI1640 (Life Technologies, Bleiswijk, The Netherlands) sup-
plemented with 10% fetal bovine serum (FBS) (Lonza, Basel, Switzerland). 
EL4 lymphoma cells and RMA-S cells were kindly provided by Cornelis 
JM Melief (Leiden University Medical Center, The Netherlands) and 
were maintained in IMDM (Life Technologies) supplemented with 10% 
FBS. Hepa1-6 cells (provided by Jurgen Seppen, Academic Medical 
Center, Amsterdam, The Netherlands) and Human embryonic kidney 
(HEK) 293T cells were maintained in DMEM (Life Technologies) supple-
mented with 10% FBS. All cells were cultured with 100 U/ml penicillin and 
100 μg/ml streptomycin (Life Technologies) at 37 °C with 5% CO2 other-
wise indicated.
Construction of rSFV replicon vectors. pSFV-helper 2 and pSFV4.2 
(pSFV), were provided by P Liljestrom (Karolinska Institute, Stockholm, 
Sweden). The plasmid DNA containing the full-length cDNA of HCV H77 
genotype 1a consensus sequence (H/FL) was kindly provided by Charles 
M Rice via Apath, LLC (AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH: p90HCVconsensuslongpU).48 pUC57-enh 
which contains the translational enhancer, foot-and-mouth disease virus 
2A auto-protease fragment, was synthesized by Eurogentec (Maastricht, 
the Netherlands). pSFVe (10,764 bps) was generated by subcloning the 
translational enhancer from pUC57-enh into pSFV between the BamHI 
and BssHII sites. pSFVeNS2′-5B′ (16,838 bps) was generated by subclon-
ing NS2′-5B′ from H/FL into pSFVe between the BssHII and NotI sites. 
pSFVeNS3/4A (12,839 bps) was constructed by cloning the BssHII-
NS3/4A-SpeI fragment, which was amplified by PCR using H/FL as a tem-
plate DNA, into pSFVe between the BssHII and SpeI sites. pSFVeNS5A/B′ 
(13,700 bps) was constructed by cloning the BssHII-NS5A/B′-NotI frag-
ment, which was amplified by PCR using H/FL as a template DNA, into 
pSFVe between the BssHII and NotI sites. All restriction enzymes were 
purchased from Thermo Fisher scientific (Landsmeer, The Netherlands). 
DNA sequences were verified by sequence analysis.
Production, purification and titer determination of rSFV. rSFVe, 
rSFVeNS2′-5B′, rSFVeNS3/4A, and rSFVeNS5A/B′ were produced as pre-
viously described.49 In brief, the plasmid DNA was in vitro transcribed 
into RNA using SP6 RNA polymerase (GE Healthcare, Diegem, Belgium). 
RNA of pSFV encoding various parts of HCV nsPs and pSFV-helper 2 were 
cotransfected at a molar ratio of 1:1 into BHK-21 cells. Likely due to the 
size of rSFVeNS2′-5B′, lower production of rSFVeNS2′-5B′ was observed. 
Therefore, transfected BHK-21 cells were cultured at 30 °C with 5% CO2 
for 78 hours instead of 37 °C for 36 hours as described previously. The 
supernatant containing the viral particles was collected and titered with 
BHK-21 cells. Titer of unpurified rSFVeNS2′-5B′ was ~2 × 107 particles/
ml and titers of other rSFV particles were ~1 × 108 particles/ml. rSFV par-
ticles were further purified on a discontinuous sucrose density gradient 
and titrated with BHK-21 cells.
Production of HCV nsPs–expressing lentivirus and HCV nsPs–expressing 
cell lines. Packaging construct (pCMV 8.91), Glycoprotein envelop plas-
mid (pMD2.G) and lentiviral vector expressing VENUS (442 New pRRL.
PPT.SF.IRES-VENUSSnucmer pre or pLenti) were kindly provided by 
Jan Jacob Schuringa (University of Groningen, The Netherlands). pLenti-
NS2′-5B′-VENUS was generated by subcloning the BglII-NS2′-5B′-BglII 
fragment from pSFVeNS2′-5B′ into the BamHI site of pLenti vector. 
pLenti-NS3/4A-VENUS was generated by removing the AgeI-NS5A/B′-
Eco81I fragment from pLenti-NS2′-5B′-VENUS. The sticky ends of AgeI 
and Eco81I were then filled by Klenow fragment and self-ligated. pLenti-
NS5A/B′-VENUS was generated by removing Bst1107I-NS2′-4A-Eco81I 
from pLenti-NS2′-5B′-VENUS. The sticky ends produced by Eco81I were 
filled in by Klenow fragment and ligated to the blunt ends produced by 
Bst1107I. To confirm the expression of HCV nsPs, HEK 293T cells were 
transfected with each plasmid DNA and the expressed nsPs were deter-
mined by western blot analysis (data not shown).
Production of lentivirus and transduction of target cells was 
performed as previously described for other lentiviruses and cells.50 In 
brief, HEK 293T cells were transiently transfected using FUGENE HD 
(Promega, Leiden, The Netherlands) with pCMV 8.91, pMD2.G and 
pLenti DNA (pLenti-NS2′-5B′-VENUS, pLenti-NS3/4A-VENUS, pLenti-
NS5A/B’-VENUS, or pLenti-VENUS) at a molar ratio of 3:0.7:3. HEK 
293T culture medium was replaced by complete medium of EL4 cells or 
Hepa1-6 cells 24 hours after transfection. The supernatant containing 
lentiviral particles were harvested, passed through a 0.45 μm filter and 
stored at −80 °C.
Hepa1-6V (V represents VENUS), Hepa1-6V-NS2′-5B′, EL4V-NS3/4A, 
EL4V-NS5A/B′ cells were generated by transducing Hepa1-6 or EL4 cells 
with corresponding lentivirus particles. Two cycles of transduction were 
performed with a 6-hour interval. Forty-eight hours after the second 
transduction, cells were harvested and the VENUS+ population was 
isolated by cell sorting using MoFlo Astrios (Beckman coulter, Woerden, 
The Netherlands). Cell sorting was performed thrice with a 1-week 
interval to produce stable cell lines. Expression of VENUS was verified 
using FACSCalibur cytometer (BD Bioscience, Breda, The Netherlands). 
Fluorescence activated cell sorting (FACS) data were analyzed using 
FlowJo analysis software (Tree Star, Ashland, OR) otherwise indicated. 
More than 95% of the sorted cells had stable expression of VENUS after 1 
month of culture (Supplementary Figure S1 and S4). VENUS expression 
of each transduced cells was verified before every experiment.
Protein expression by pulse labeling. BHK-21 cells (5 × 105 cells in a well 
of a six-well plate) were incubated with 5 × 106 rSFVe, rSFVeNS2′-5B′, 
rSFVeNS3/4A or rSFVeNS5A/B′. After 6 hours, supernatant was removed 
and the cells were washed with PBS three times. The cells were then fur-
ther cultured in methionine-free DMEM for 30 minutes followed by 
labelling with 35S-methionine (0.37 Mbq/well) for 1 hour (PerkinElmer, 
Groningen, The Netherlands). After 1, 6, or 18 hours of [35S]-methionine 
labeling, cells were washed with cold PBS and then lysed with TENT lysis 
buffer (50 mmol/l Tris–HCl, 5 mmol/l EDTA, 150 mmol/l NaCl, and 0.5% 
Triton-X-100, pH7.5) containing 0.2 mmol/l phenyl-methane-sulphonyl-
fluoride. Cell lysate was analyzed by SDS/PAGE and autoradiography.
Synthetic peptides. The synthetic peptides HCV1629–1637 GAVQNEVTL 
(H-2Db), HCV2252–2259 ILDSFDPL (H-2Kb), OVA257–264 SIINFEKL (H-2Kb) 
and human papillomavirus-16-E749–57 RAHYNIVTF (H-2Db) were manu-
factured by the department of Immunohematology, Leiden University 
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Medical Center, The Netherlands. The purities of the synthetic peptide 
were analyzed with HPLC. All synthetic peptides have a purity of >90%.
Peptides stabilization assay. RMA-S cells were cultured at 26 °C with 5% 
CO2 for 48 hours to induce expression of MHC class I. Cells were then 
incubated with various concentrations of synthetic peptides at 26 °C for 
4 hours, followed by cultured at 37 °C for 1 hour. Cells were harvested, 
washed once with 0.5% bovine serum albumin/PBS and stained with APC-
anti-H-2Kb Ab (clone: AF6-88.5.5.3) and FITC-anti-H-2Db Ab (clone: 
28-14-8) (eBioscience, Vienna, Austria) at 4 °C for 20 minutes. The sur-
face expression of MHC class I molecules were analyzed by FACSCalibur 
cytometer (BD Bioscience).
Mice. Specific pathogen-free female inbred C57BL/6JOlaHsd (H-2b) 
mice were obtained from a commercial vendor (Harlan CPB, Zeist, The 
Netherlands) and were kept under the institute guidelines of the University 
of Groningen, The Netherlands. All mice were 8 to 10 weeks of age at the 
start of all experiments. All animal experiments (DEC number: 5946) were 
approved by the local Animal Experimentation Ethical Committee (the 
Institutional Animal Care and Use Committee of the University Medical 
Center of Groningen).
Prime-boost immunizations. Mice were intramuscularly primed and 
boosted immunized with a 2-week interval with 5 × 106 rSFV (rSFVe, 
rSFVeNS2′-5B′, rSFVeNS3/4A, or rSFVeNS5A/B′) in 50 μl (25 μl/thigh 
muscle) under anesthesia (isoflurane/O2). For negative controls, the same 
volume of PBS was injected intramuscularly.
Phenotypic analysis of NS3-specific cells. Splenocytes and blood cells were 
stained with PE-GAVQNEVTL-dextramers (Immudex, Copenhagen, 
Denmark) in 5% FBS/PBS for 10 minutes at room temperature. Followed by 
staining with PE-Cy7-anti-CD8a Ab (clone: 53–6.7), PerCP-Cyanine5.5-
anti-CD44 Ab (clone: IM7), APC-anti-CD62L Ab (clone: MEL-14), and 
eFluor 450-anti-CD127 Ab (clone: A7R34) for 20 minutes at 4 °C. All anti-
bodies were purchased from eBioscience. Death cells were excluded with 
4′-6′-diamidino-2-phenylindole staining. FACS analysis was conducted 
with LSR-II flow cytometer (BD Bioscience).
Identification of multifunctional HCV-specific cells. Splenocytes isolated 
from immunized mice were cultured with the 100 Gy-irradiated Hepa1-6 
cells (Hepa1-6V-NS2′-5B′ cells or Hepa1-6V cells) at a ratio of 25:1 or with 
10 μg/ml of synthetic peptides. The Hepa1-6 cells were cultured in the pres-
ence of 50 U/ml of recombinant mouse IFN-γ (Peprotech, London, UK) for 
48 hours before coculturing with splenocytes. Splenocytes were cultured 
in the presence of anti-CD28 Ab (clone: PV-1, Bioceros B.V., Utrecht, The 
Netherlands), eFluor 660-anti-CD107a Ab (clone: eBio1D4B) and eFluor 
660-anti-CD107b Ab (clone: eBioABL-93) in a 96-well plate at 37 °C with 
5% CO2. One hour after culture, brefeldin A (1 mg/ml) was added and the 
cultures were further incubated for 4 hours. Cells were then harvested, 
washed and stained with LIVE/DEAD fixable violet dead cell stain kit (Life 
Technologies) according to manufacturer’s manuals. Followed by surface 
staining with PE-Cy7-anti-CD8a Ab at 4 °C for 20 minutes and intracel-
lular staining with PerCP-Cyanine5.5-anti-IFN-γ Ab (clone: XMG1.2), 
FITC-anti-TNF-α Ab (clone: MP6-XT22) and APC-Cy7-IL-2 Ab (clone: 
JES6-5H4) at 4 °C for 30 minutes. eFluor 660-anti-CD107a, eFluor 
660-anti-CD107b and PerCP-Cyanine5.5-anti-IFN-γ antibodies were pur-
chased from eBioscience; FITC-anti-TNF-α and APC-Cy7-IL-2 antibod-
ies were purchased from BD Biosciences. FACS analysis was conducted 
with LSR-II flow cytometer, and data were analyzed using FCOM tool of 
WinList software (Verity Software House, Topsham, ME) and presented as 
pie charts using SPICE version 5.3 (NIAI freeware).
Bulk CTL assay. The stimulator cells, Hepa1-6V-NS2′-5B′ cells, were cultured 
in the presence of 50 U/ml recombinant murine IFN-γ for 48 hours. Hepa1-
6V-NS2′-5B′ cells were then irradiated (100 Gy) and cocultured with effector 
cells, splenocytes, at a ratio of 1:25 in a T25 flask at 37 °C with 5% CO2. 
Recombinant human IL-2 (5 U/ml) (Peprotech) was added on day 3 and day 
5 of the culture. After 7 days culture, splenocytes were harvested and cocul-
tured with 51Chromium (51Cr)-labeled target cells (Hepa1-6V-NS2′-5B′ cells, 
EL4 pulsed with GAVQNEVTL or EL4 pulsed with ILDSFDPL). Target cells 
were cultured in the presence of recombinant murine IFN-γ (50 U/ml) 48 
hours before coculture with effector cells. Target cells were labeled with 51Cr 
(100 μCi/2 × 106 cells) (PerkinElmer) in the presence or absence of synthetic 
peptides (10 μg/ml) for 1 hour at 37 °C. Coculture of effector cells and tar-
get cells were performed in 96 well plate at 4 E:T ratios in triplicates at 37 
°C with 5% CO2. After 4 hours of culture, supernatants were harvested and 
analyzed with a RiaStar manual gamma counter (Packard, Meriden, CT). 
The percentage of cytotoxicity was calculated according to the formula: % 
specific release = ((experimental release − spontaneous release)/(maximal 
release − spontaneous release)) count per minute (c.p.m).
In vivo CTL assay. Splenocytes were isolated from naïve syngeneic mice 
and were pulsed with synthetic peptides at 10 μg/ml in IMDM supple-
mented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomy-
cin for 2 hours at 37 °C with 5% CO2. The peptide-pulsed splenocytes 
were then washed and resuspended in PBS. GAVQNEVTL-pulsed and 
SIINFEKL-pulsed splenocytes were labeled with 5 μmol/l of CFSE (Life 
Technologies) and 0.1 μmol/l of CFSE for 20 minutes at 37 °C, respectively. 
ILDSFDPL-pulsed splenocytes were labeled with 30 μg/ml of tetramethyl-
rhodamine-6-isothiocyanate (TRITC) (Life Technologies) for 10 minutes 
at 37 °C. Differentially labeled cells were washed, resuspended in PBS and 
combined at a 1:1:1 ratio for intravenous adoptive transfer. Each mouse 
received 2 × 106 cells of each population. After 14 hours, splenocytes were 
isolated and analyzed using LSR-II flow cytometer. The percentage of 
cytotoxicity was calculated with the formula: % cytotoxicity = 1 − (% of 
relevant peptides-pulsed target (GAVQNEVTL or ILDSFDPL) in rSFV-
immunized mice/% of irrelevant peptides-pulsed target (SIINFEKL) in 
immunized mice)/(% of relevant peptides-pulsed target in PBS-treated 
mice/% of irrelevant peptides-pulsed target in PBS-treated mice).
Tumor inoculation. Mice were inoculated subcutaneously in their right 
flank with 5 × 105 EL4V-NS3/4A or EL4V-NS5A/B′ cells suspended in 0.2 ml 
PBS. The volume of tumor was measured by caliper. Cylinder tumor is cal-
culated with the formula 0.7854 × width2 × length (cm3). Round tumor is 
calculated with the formula 0.5236 × diameter3 (cm3). Mice were eutha-
nized when the tumor volume reached 1 cm3.
Tumor cells isolation. Tumor excised from mice was cut into small 
pieces and suspended in 5 ml of William’s E + Glutamax medium (Life 
Technologies) containing 1 mg/ml of collagenase A (Roche Applied 
Science, Almere, The Netherlands). Tumor suspension was transferred 
into a gentleMACS C-tube and homogenized with the program “m_imp-
TUMOR4” with a gentleMACS dissociator (Miltenyi Biotec, Leiden, The 
Netherlands) followed by 30 minutes incubation at 37 °C. Homogenization 
and incubation were performed twice. After the second incubation, cell 
suspension was passed through a 70-μm strainer (BD Bioscience), 
wash once with 0.5% bovine serum albumin/PBS and analyzed with 
FACSCalibur cytometer.
Statistical analysis. Differences between two groups were determined 
with the Mann–Whitney U–test. Differences between two survival curves 
were calculated using the log-rank (Mantel-Cox) test. All data were ana-
lyzed with GraphPad Prism software (La Jolla, CA). P < 0.05 was consid-
ered statistically significant.
SUPPLEMENTARY MATERIAL
Figure S1. VENUS expression of HCV nsPs–expressing Hepa1-6 cell 
lines.
Figure S2. Stabilization of MHC class I molecules on RMA-S cells 
through binding of HCV peptides.
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Figure S3. No induction of polyfunctional HCV-specific T cells upon 
stimulation with Hepa1-6V cells.
Figure S4. VENUS expression of HCV nsPs–expressing EL4 cell lines.
Figure S5. Therapeutic effect of rSFV immunizations against HCV 
nsPs–expressing EL4 cells.
Figure S6. Effect of early immunization with rSFVeNS2′-5B′ and 
rSFVeNS3/4A against EL4V-NS3/4A cells.
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